<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075673</url>
  </required_header>
  <id_info>
    <org_study_id>ICC3102</org_study_id>
    <nct_id>NCT00075673</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study of Weekly Administration of Oral Navelbine in Combination With the COX-2 Inhibitor Celebrex in Relapsed and/or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for&#xD;
      tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to&#xD;
      stop tumor cells from dividing so they stop growing or die. Combining vinorelbine with&#xD;
      celecoxib may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to determine the effectiveness of combining vinorelbine with celecoxib&#xD;
      in treating women who have relapsed or metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed&#xD;
           or metastatic breast cancer.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive oral celecoxib twice daily on days 1-21 and oral vinorelbine on days 7, 14,&#xD;
      and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of celecoxib and vinorelbine until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of vinorelbine and celecoxib in women with relapsed or metastatic breast cancer.</measure>
    <time_frame>Courses (21 days) repeat every 21 days in the absence of disease progression or unacceptable toxicity.</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine ditartrate</intervention_name>
    <description>Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast&#xD;
&#xD;
               -  Recurrent or metastatic (stage IV) disease&#xD;
&#xD;
               -  Incurable disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Stable brain metastases allowed&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST/ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No clinically significant proteinuria&#xD;
&#xD;
          -  No impaired renal function&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No inadequately controlled hypertension&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No disorder that would alter gastrointestinal motility or absorption&#xD;
&#xD;
          -  No dysphagia&#xD;
&#xD;
          -  Able to swallow tablets or capsules&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No hypersensitivity to celecoxib&#xD;
&#xD;
               -  No prior urticaria, asthma, or other allergic-type reaction after taking aspirin&#xD;
                  or other nonsteroidal anti-inflammatory drugs&#xD;
&#xD;
          -  No allergy to sulfa&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 3 weeks since prior trastuzumab (Herceptin®) and recovered&#xD;
&#xD;
          -  No concurrent hematopoietic growth factors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant chemotherapy allowed&#xD;
&#xD;
          -  Prior chemotherapy for recurrent or metastatic disease allowed&#xD;
&#xD;
          -  No prior vinorelbine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 2 weeks since prior hormonal therapy&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant hormonal therapy allowed&#xD;
&#xD;
          -  Prior hormonal therapy for recurrent or metastatic disease allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy for metastatic disease&#xD;
&#xD;
          -  Prior adjuvant radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior investigational anticancer agents and recovered&#xD;
&#xD;
          -  At least 1 week since prior cyclooxygenase-2 (COX-2) inhibitors, except celecoxib&#xD;
&#xD;
          -  No concurrent administration of any of the following drugs:&#xD;
&#xD;
               -  Lithium&#xD;
&#xD;
               -  Fluconazole&#xD;
&#xD;
               -  Aluminum antacids&#xD;
&#xD;
               -  Magnesium antacids&#xD;
&#xD;
          -  Concurrent H_2 blocking agents or proton pump inhibitors allowed for the treatment of&#xD;
             dyspepsia or gastroesophageal reflux disease&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paula Silverman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <name_title>Paula Silverman, MD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

